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ABSTRACT 
The present study was aimed to formulate and evaluate floating tablets of indomethacin by wet granulation method. Indomethacin is 
used as a potent anti-inflammatory drug with prompt anti pyretic action, mainly used for the treatment of osteoarthritis with half-life 
of 4.5 hrs. Indomethacin is stable in neutral or slightly acidic media. In this study, excipients like HPMC 5cps, sodium bi carbonate 
were incorporated in a nine different concentrations (F1-F9) along with other excipients (PVP K30, lactose, talc, and magnesium 
stearate) to formulate floating tablets by wet granulation method. Then all the nine formulations were evaluated for uniformity of 
weight, hardness, thickness, friability test, floating lag time, drug content, dissolution studies and stability studies. The dissolution 
profile of trial-6 (formulation 6) was observed to be better than other formulations. In trial-6 indomethacin was formulated as a 
floating tablet by using HPMC 5cps (120 mg) as a matrix forming polymer and sodium bi carbonate (40 mg) as a gas generating 
agent. Trial-6 formulation showed a good dissolution profile for a controlled period of time which was noticed to be as 97.78 % at 
the end of 12th hour. Thus, it can be concluded that the floating drug delivery system of indomethacin using the appropriate polymers 
in right amount may enhance the activity of the drug by prolonging the gastric residence time or reducing the floating lag time.  
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INTRODUCTION 
Gastric transit time is valuable asset for dosage forms, 
which reside in the stomach for a long period of time 
than conventional dosage form. Conventional oral 
dosage forms (such as tablets, capsules) provide specific 
drug concentration in systemic circulation without 
offering any control over drug delivery and also cause 
great fluctuations in plasma drug levels.
1,2 
 Many 
attempts have been made to develop sustained release 
preparations with extended clinical effects and reduced 
dosing frequency.
3,4 
One of the such approach can be 
floating systems which are low density systems that 
have sufficient buoyancy to float over the gastric 
contents and remain in the stomach for a prolonged 
period. While the system floats over the gastric contents, 
the drug is released slowly at the desired rate, which 
results in increased gastro-retention time and reduces 
fluctuation.
5,6 
Floating drug delivery systems have an 
advantage to reduce the dose frequency and improves 
patient compliance. It thus improves the therapy.
 7
 The 
fluctuations in plasma drug concentration are minimized, 
and thus concentration-dependent adverse effects that 
are associated with peak concentrations can be 
prevented. This feature is of special importance for 
drugs with a narrow therapeutic index. That makes it 
possible to obtain certain selectivity in the elicited 
pharmacological effect of drugs that activate different 
types of receptors at different concentrations.
8,9 
Floating 
drug delivery systems reduces the drug concentration 
fluctuation over a critical concentration and thus 
enhances the pharmacological effects and improves the 
clinical outcomes.
 10 
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MATERIALS AND METHODS 
Indomethacin was obtained as gift sample from sigma 
aldrich chemicals pvt. Ltd. Bangalore, India. Different 
polymers and excipients like lactose, hydroxy propyl 
methyl cellulose 5cps, Sodium bicarbonate, PVPK30, 
Talc, Magnesium stearate were purchased from  Central 
drug house Ltd. New Delhi, India. All other ingredients 
used were of laboratory grade. 
Preformulation studies:  
The parameters like melting point, IR spectra, angle of 
repose, bulk density, tapped density, Hausner’s ratio 
were determined as the part of preformulation studies.
11
 
Drug-excipient compatibility studies: 
Compatibility studies were carried out to know the 
possible interactions between indomethacin and 
excipients used in the formulation. Physical mixtures of 
drug and excipients were prepared to study the 
compatibility using the Infra Red spectrophotometer.
12
. 
Preparation of indomethacin floating tablet:  
All the ingredients (except glidants and lubricant) as 
shown in Table1 were weighed separately, mixed 
thoroughly in poly bag for 10 minutes to ensure uniform 
mixing and the mixture was passed through sieve no.60. 
Granulation was done with a solution of calculated 
quantity of PVP K30 in sufficient isopropyl alcohol. The 
wet mass was passed through sieve no. 12, and dried at 
75°C for 2 hours. The dried granules were sized by sieve 
no. 18 and mixed with magnesium stearate and talc. The 
blend thus obtained was compressed (8 mm diameter, 
flat punches) using a single station tablet press machine 
(Cip, Ahmadabad).
13 
 
Table 1: Formulation batches of indomethacin floating tablet by wet granulation method. 
S.NO. Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
01 Indomethacin 75 75 75 75 75 75 75 75 75 
02 HPMC 5cps 60 80 120 60 80 120 60 80 120 
03 Sodium bicarbonate  20 20 20 40 40 40 50 50 50 
04 PVP K30 20 20 20 20 20 20 20 20 20 
05 Lactose  30 30 30 30 30 30 30 30 30 
06 Talc  5 5 5 5 5 5 5 5 5 
07 Magnesium stearate  10 10 10 10 10 10 10 10 10 
    
Evaluation of floating tablets: 
1. Uniformity of weight: Twenty tablets were weighed 
individually and the average weight was determined. 
The percentage deviation was calculated and checked 
for weight variation as per IP
14
. Deviation of weight 
variation is given in table 2. 
Table 2: % Deviation for Weight Variation 
Average Weight of tablet (mg) % Deviation 
80mg or less                                           10 
80 mg to 250 mg  7.5 
250 mg or more                                       5
 
2. Hardness: Hardness or tablet crushing strength (fc ), 
is the force required to break a tablet in a diametric 
Compression. This compression force was measured 
using Monsanto tablet hardness tester for all the 
batches
15
. It is expressed in kg/cm
2
. 
3. Thickness: Thickness of tablets is important for 
uniformity of tablet size. Thickness was measured using 
Vernier Calipers on 3 randomly selected samples.
16
 
4. Friability test:  
Friability is the measure of tablet strength. Roche 
friabilator was used for testing the friability using the 
following procedure. Twenty tablets were weighed 
accurately and placed in the tumbling apparatus that 
revolves at 25 rpm dropping the tablets through a 
distance of six inches with each revolution. After 4 
minutes, the tablets were weighed and the percentage 
loss in tablet weight was determined using the below 
given formula.
17 
       
     
                                                   
                         
      
5. Floating lag time:  
The lag time was carried out in beaker containing 250 
ml of pH 1.2 buffer solution as a testing medium 
maintained at 37
°
C. The time required for the tablet to 
rise to the surface and float was determined as floating 
lag time in minutes.
18
 
 6. Drug content: 
Five tablets were weighed individually, and powdered. 
The drug was extracted in pH 1.2 and the solution was 
filtered through whatman filter paper. The absorbance 
was measured at 237 nm after suitable dilution using a 
shimadzu UV spectrophotometer.
19 
 
7. Dissolution studies: 
The release rate of indomethacin from floating tablets 
was determined using USP Dissolution Testing 
Apparatus II (Paddle type). The dissolution test was 
performed using 900 ml of pH 1.2 buffer solution, at 37 
± 0.5
°
C and 50 rpm. Aliquot volume was withdrawn 
from the dissolution apparatus hourly for 12h, and the 
samples were replaced with fresh dissolution medium. 
After filtration and suitable dilution the amount of drug 
release was determined from the calibration curve.
20
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Details of Dissolution Test: 
1. Apparatus    : USP Type II 
2. Volume of medium    : 900 ml 
3. Temperature    : 37 
°
C 
4. Paddle Speed    : 50 rpm 
5. Dissolution medium used: pH 1.2 buffer solution 
6. Aliquot taken at each time interval: 5 ml 
8.  Stability studies of the standard formulations:
 
Stability testing of drug products begins as a part of 
drug discovery and ends with the demise of the 
compound or commercial product. To assess the drug 
and formulation stability, the stability studies were 
carried out on the one most satisfactory formulation as 
per ICH guidelines Q1C.
 21
 The most satisfactory 
formulation F6 was sealed in aluminum packaging and 
was kept in humidity chamber maintained at 35 ± 2 °C / 
60 ± 5 % RH and 40 ± 2 °C / 75 ± 5 %RH for 3 months. 
It was then evaluated for various parameters to check 
the stability and efficacy of the product. 
RESULT AND DISCUSSION 
The prepared floating tablets were evaluated for various 
physical properties. The physical attributes of the 
floating tablets were found to be satisfactory. Typical 
tablets defects were not observed. Preformulation 
studies were done as mentioned in methods. The melting 
point was observed to be (157
0
C-159
0
C) which shows 
that the indomethacin drug was pure. Formulation of 
floating tablets was prepared as per wet granulation 
method. The prepared tablets were then evaluated for 
parameters such as weight variation, Hardness, friability 
and thickness, diameter, Floating lag time.  
To check the purity of drug, IR spectrum of 
Indomethacin was taken on Jasco FTIR 4000. The 
spectra shows characteristic peaks of Indomethacin 
similar to the standard spectra given in the instrumental 
analysis. The IR spectrum is given in the figure 1, and 
drug peaks are given in table 3. 
To check the interaction between drug and Excipients, 
used in the formulations, IR studies were performed. In 
IR study, it was found that all the prominent peaks 
which were present in individual graphs of 
Indomethacin were also present in IR of physical 
mixture between drug and Excipients. Thus we can say 
that there was no significant interaction between drug 
and Excipients. The drug and excipients spectrum are 
given in the figure 2 and peaks are given in table 4. 
 
 
Figure 1: FTIR Spectra of Indomethacin 
 
 
Figure 2: FTIR Spectra of Tablet of indomethacin and excipients. 
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Table 3: Characteristic IR absorption peaks of functional groups in Indomethacin 
Sr. No. Particulars Functional Groups Characteristic Peaks(cm
-1
) 
1 Indomethacin  C-Cl stretching 802 
C-O stretching ether  1260,1065 
O-H(carboxy) str.  2965,3275 
-C=O-(alpha & beta unsaturated) 1712 
Aromatic C=C Stretch  1586 
C=O(Carboxylic acid)  1742 
  C-N stretch amine 1220 
  C-H stretch alkane 2988,2834 
 
Table 4: Characteristic IR absorption of functional groups for drug and Excipients interaction 
Sr. No. Particulars Functional Groups Characteristic Peaks(cm
-1
) 
1 Indomethacin + Excipients   C-O stretching  1115. 
O-H  2765, 2739 
C-Cl stretching 802 
C-O stretching ether  1260,1066 
Aromatic C=C Stretch  1583 
C=O(Carboxylic acid)  1748 
  C-H stretching alkane 2800,2900 
  -C=O-(alpha & beta unsaturated) 1713 
  Aromatic C=C Stretch  1583 
 
The powder mixtures prepared for compression of 
floating tablets were evaluated for their flow properties. 
Angle of repose was in the range of 21.12- 29.94. 
Tapped density was found to be in the range of 0.50-
0.62g/ml). Carr’s index was in the range of 6.37-12.37 
and Hausner’s ratio was in the range of 1.06-1.13 for the 
powder mixture of different formulation. All the result 
indicated that, the powder blends possess good 
flowability and compressibility properties. (Table 5).  
 
Table 5: Preformulation parameters for powder blend 
Batch Bulk density 
(gm/ml) 
Tap density 
(gm/ml) 
Carr’s index Hausner’s 
ratio 
Angle of repose 
F1 0.512±0.065 0.575±0.045 10.95±0.75 1.123±0.84 26.28±0.25 
F2 0.530±0.054 0.598±0.054 11.37±0.45 1.122±0.48 26.97±0.43 
F3 0.570±0.035 0.616±0.065 7.46±0.36 1.087±0.59 27.33±0.56 
F4 0.578±0.046 0.620±0.035 6.77±0.75 1.072±0.23 29.94±0.47 
F5 0.425±0.025 0.485±0.025 12.37±0.35 1.141±0.19 22.92±0.38 
F6 0.470±0.015 0.502±0.065 6.37±0.26 1.068±0.54 23.21±0.74 
F7 0.417±0.075 0.471±0.054 11.46±0.45 1.129±0.62 21.12±0.58 
F8 0.421±0.048 0.478±0.055 11.92±0.76 1.135±0.86 22.24±0.59 
F9 0.445±0.067 0.487±0.065 8.62±0.15 1.094±0.46 21.22±0.62 
 
The weight of the sample tablets varied between 246-
249 mg. The variation in weight was within the range of 
±5%, Complying with pharmacopoeial specifications, 
The hardness of different formulations was found to be 
4.3-4.5 Kg/cm
2
, indicating satisfactory mechanical 
strength. The friability was below 1% for all the 
formulations, which is an indication of good mechanical 
resistance of the tablet. Diameter of tablets were 
measured and found in the range of 9.9 to 10 mm and 
Thickness of the tablets were found in the range of 2.9 
to 3 mm.  
Floating lag time varied between 1.0-5.0 minutes. 
Floating property of the tablet is the governed by the 
swelling (hydration) of the tablet, when it contacts with 
the gastric fluid which in turn in results in increase in 
the bulk volume and pressure of internal voids in the 
centre of the tablet. Floating properties of the tablets 
could be improved with gas generating agent which is 
sodium bi carbonate. It generates gas when it comes in 
with an acidic environment of the stomach. This gas 
entraps into the matrix of water soluble of polymers and 
the formulation floats in acidic environment of the 
stomach. As the concentration of the HPMC increased, 
the swelling of the tablet increased, but the drug release 
decreased.   
In vitro drug release data of all the floating formulation 
was subjected to goodness of fit test by linear regression 
analysis according to Zero order, First order, Higuchi, 
Korsmeyer-peppas models to ascertain the mechanism 
of drug release. The result of in vitro percentage drug 
release and linear regression analysis including 
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regression coefficients are summarized in (Table 7, 8 
and plots shown in Figure 3 & 4-15). 
From the above data, Among all the design Batches of 
tablet F6 was taken as on optimized batch for tablet 
optimization, Because F6 shows less friability <1, good 
hardness 4.5kg/cm
2
, less floating lag time 2.5 (min). 
(Table 6) 
 
Table 6: Tablet diameter, Tablet thickness, Hardness, Friability and Weight Variation: 
Formulations Tablet 
Diameter 
(mm) 
Thickness 
(mm) 
Hardness 
(Kg/cm
2
) 
Friability 
(%) 
Weight 
variation 
(mg) 
Floating lag 
time (min) 
Drug content 
(%) 
F1 9.98±0.04 2.98±0.06 4.5±0.08 0.23±0.06 248±6.66 4.5 99.20±0.39 
F2 9.99±0.03 2.97±0.07 4.3±0.16 0.21±0.06 249±6.90 5.0 98.45±0.25 
F3 10.0±0.00 2.98±0.06 4.4±0.08 0.25±0.19 246±6.73 4.6 99.80±0.20 
F4 10.0±0.00 2.98±0.06 4.3±0.14 0.32±0.03 248±6.66 3.0 98.30±0.45 
F5 9.99±0.03 3.00±0.00 4.5±0.08 0.42±0.07 249±6.90 2.8 97.80±0.60 
F6 9.98±0.04 2.98±0.06 4.5±0.08 0.08±0.01 248±6.66 2.5 98.65±0.25 
F7 10.0±0.00 3.00±0.00 4.3±0.14 0.34±0.06 246±6.73 1.0 98.60±0.35 
F8 9.99±0.03 2.97±0.07 4.4±0.08 0.23±0.06 249±6.90 1.2 98.75±0.25 
F9 10.0±0.00 3.00±0.00 4.5±0.08 0.11±0.05 249±6.90 1.5 99.50±0.20 
 
It can be seen that optimized formulation F6 has Zero 
order, Higuchi and peppas model was fitted. From that 
data,It was evident that the drug Release by non-fickian 
diffusion mechanism. Because the value of r
2 
of Zero 
order, Higuchi’s and peppas were 0.991,0.889 and 0.972 
accordingly and ‘n’ value of peppas Equation was 
0.903. This data reveals the drug release follows non 
fickian diffusion Mechanism.(Table 8 and fig. 4-15) 
 
 
Figure 3: Percent drug release of Batches F1 to F9. 
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Table 7: Release kinetics of batches F1 to F9 
 
Formulations 
Regression coefficient (R
2
) Release 
exponent (n) 
Drug release 
mechanism 
Zero order First order Higuchi Korsmeyer-
Peppas 
  
F1 0.980 0.053    0.880 0.916 0.763 Non-fickian transport  
F2 0.989 0.060    0.896 0.943 0.821 Non-fickian transport 
F3 0.986 0.058 0.868 0.947 0.998 Non-fickian transport 
F4 0.983 0.044 0.900 0.928 0.726 Non-fickian transport 
F5 0.986 0.069 0.903 0.927 0.784 Non-fickian transport 
F6 0.991 0.057 0.889 0.972 0.903 Non-fickian transport 
F7 0.972 0.050 0.915 0.936 0.715 Non-fickian transport 
F8 0.988 0.089 0.884 0.856 0.766 Non-fickian transport 
F9 0.993 0.080 0.901 0.967 0.849 Non-fickian transport 
 
 
Figure 4: % Cumulative amount of drug release v/s 
time of zero order kinetic(F1-F3) 
 
Figure 5: % Log cumulative percent drug remaining 
v/s time of First order kinetic(F1-F3) 
 
Figure 6: Cumulative percent drug release v/s the 
square root of time for higuchi model kinetics(F1-F3) 
 
Figure 7: Log cumulative percent of drug released v/s 
log time for korsemeyr-peppas kinetics 
 
Figure 8: % Cumulative amount of drug release v/s 
time of zero order kinetic (F4-F6) 
 
Figure 9: % Log cumulative percent drug remaining 
v/s time of First order kinetic (F4-F6) 
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Figure 10: Cumulative percent drug release v/s the 
square root of time for higuchi model kinetics(F4-F6) 
 
 
Figure 11: Log cumulative percent of drug released 
v/s log time for korsemeyr-peppas kinetics. 
 
 
Figure 12: % Cumulative amount of drug release v/s 
time of zero order kinetic(F7-F9). 
 
Figure 13: % Log cumulative percent drug 
remaining v/s time of First order kinetic 
 
Figure 14: Cumulative percent drug release v/s the 
square root of time for higuchi model kinetics 
 
Figure 15: Log cumulative percent of drug released 
v/s log time for korsemeyr-peppas kinetics 
Stability of optimized formulation (F-6) was performed 
for 1 and 3 month. In-vitro drug release study shown 
(Table 9) after 1 and 3 month , the drug release for 12 
hrs obtained within range of targeted release profile and 
there was no drastic change in drug content, weight, 
floating lag time, friability, floating time, % Cumulative 
drug release. It showed that there was no change in the 
formulation after 1 and 3 month. It indicates that 
prepared formulation was stable. 
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Table 8: Physical evaluation parameters of formulation F6 during stability study 
Sampling Time 
Interval 
(Months) 
Weight 
( mg) 
Floating Lag 
Time (min) 
Floating 
Time 
(Hrs.) 
% Friability Drug Content 
uniformity 
%CDR 
Initial study 248±6.66 2.5 >12 0.08±0.01 98.65±0.25 97.78±3.18 
1 Month 248±6.60 2.0 >12 0.06±0.05 98.37±0.30 97.78±3.12 
3 Months 248±6.70 2.3 >12 0.10±0.02 98.10±0.15 97.78±3.22 
 
CONCLUSION 
The floating tablets for indometahcin (F1-F9) were 
successfully prepared using HPMC 5cps matrix forming 
polymer and Sodium bi carbonate as gas generating 
agent by wet granulation techniques. The optimized 
formulation F6 has shown better sustained drug release 
and which has good floating properties. The release 
profile of optimized formula, fitted best to korsemeyr-
peppas model with R
2 value of 0.972. as the ‘n’ value for 
korsemeyr-peppas model was found to be 0.903 it 
follows non-fickian diffusion mechanism. It shown has 
good stability at storage condition. 
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